Get the Stockscreener App
44.82
1.33%
0.6149
Royalty Pharma Plc stock is traded at $44.82, with a volume of 1.33M.
It is up +1.33% in the last 24 hours and up +11.53% over the past month.
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
See More
Previous Close:
$44.21
Open:
$42.94
24h Volume:
1.33M
Relative Volume:
0.34
Market Cap:
$19.15B
Revenue:
$2.35B
Net Income/Loss:
$1.30B
P/E Ratio:
25.63
EPS:
1.7487
Net Cash Flow:
$1.05B
1W Performance:
+2.56%
1M Performance:
+11.53%
6M Performance:
+23.79%
1Y Performance:
+38.91%
1-Day Range:
$42.50
$44.93
1-Week Range:
$42.50
$44.93
52-Week Range:
$29.66
$44.93
Royalty Pharma Plc Stock (RPRX) Company Profile
Name
Royalty Pharma Plc
Sector
Industry
Phone
(212) 883-0200
Address
110 EAST 59TH STREET, NEW YORK, NY
Compare RPRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RPRX
Royalty Pharma Plc
|
44.83 | 18.89B | 2.35B | 1.30B | 1.05B | 1.7487 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.41 | 117.59B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
760.69 | 79.81B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
830.46 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.02 | 42.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.04 | 39.11B | 4.98B | 69.60M | 525.67M | 0.5198 |
Royalty Pharma Plc Stock (RPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-30-26 | Upgrade | UBS | Neutral → Buy |
| Sep-30-25 | Initiated | Goldman | Buy |
| May-16-25 | Initiated | Morgan Stanley | Overweight |
| Jun-03-24 | Downgrade | UBS | Buy → Neutral |
| Jun-14-22 | Resumed | UBS | Buy |
| May-13-22 | Initiated | Scotiabank | Sector Outperform |
| Apr-27-22 | Initiated | Goldman | Buy |
| Apr-14-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Oct-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-30-21 | Initiated | Tigress Financial | Buy |
| Nov-09-20 | Upgrade | UBS | Neutral → Buy |
| Jul-14-20 | Initiated | Evercore ISI | In-line |
| Jul-13-20 | Initiated | BofA Securities | Buy |
| Jul-13-20 | Initiated | Citigroup | Neutral |
| Jul-13-20 | Initiated | Cowen | Outperform |
| Jul-13-20 | Initiated | Goldman | Neutral |
| Jul-13-20 | Initiated | JP Morgan | Neutral |
| Jul-13-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-13-20 | Initiated | SunTrust | Buy |
| Jul-13-20 | Initiated | UBS | Neutral |
View All
Royalty Pharma Plc Stock (RPRX) Latest News
Earnings call transcript: Royalty Pharma beats Q4 2025 forecasts with strong EPS - Investing.com India
RPRX: Double-digit growth, early capital deployment, and strong 2026 outlook with cost savings - TradingView
Royalty Pharma Q4 Earnings Call Highlights - Yahoo Finance
Royalty Pharma plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Royalty Pharma plc Provides Earnings Guidance for the Full Year 2026 - marketscreener.com
Royalty Pharma plc SEC 10-K Report - TradingView
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings - Finviz
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat - Chartmill
Royalty Pharma Reports Q4 and Full Year 2025 Results - TradingView
Royalty Pharma's Q4 Net Income, Revenue Rise - marketscreener.com
Royalty Pharma reports Q4 portfolio receipts of $874M - TipRanks
Royalty Pharma Plc Bottom Line Advances In Q4 - Nasdaq
Royalty Pharma Q4 Earnings Report: What Investors Need to Know - Benzinga
Royalty Pharma earnings in focus after $4.7B deal spree - Investing.com
Royalty Pharma's Earnings: A Preview - Benzinga
Exploring Analyst Estimates for Royalty Pharma (RPRX) Q4 Earnings, Beyond Revenue and EPS - Yahoo Finance Australia
UBS and Citi are bullish on Royalty Pharma plc (RPRX) – here’s why - MSN
UBS and Citi Are Bullish on Royalty Pharma Plc (RPRX) – Here’s Why - Insider Monkey
Allianz Asset Management GmbH Sells 127,319 Shares of Royalty Pharma PLC $RPRX - MarketBeat
What To Expect From Royalty Pharma's (RPRX) Q4 Earnings - Finviz
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings - Yahoo Finance UK
Alps Advisors Inc. Acquires New Shares in Royalty Pharma PLC $RPRX - MarketBeat
Shorts Report: Will Royalty Pharma plc benefit from rate cutsJuly 2025 Outlook & Stock Timing and Entry Methods - baoquankhu1.vn
Rally Mode: Should I add Phoenix Laser Systems Inc Preferred Security stock to my portfolio2025 Market Sentiment & Weekly High Momentum Picks - baoquankhu1.vn
Thrivent Financial for Lutherans Trims Stake in Royalty Pharma PLC $RPRX - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release - Finviz
Royalty Pharma PLC (NASDAQ:RPRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Royalty Pharma (NASDAQ:RPRX) Reaches New 1-Year HighHere's What Happened - MarketBeat
Royalty Pharma EVP Coyne sells $10.3 million in shares By Investing.com - Investing.com UK
C WorldWide Group Holding A S Raises Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Homestead Advisers Corp Sells 37,000 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma EVP Coyne sells $10.3 million in shares - Investing.com
3 Mid-Cap Stocks We Keep Off Our Radar - Finviz
(RPRX) Risk Channels and Responsive Allocation - Stock Traders Daily
Royalty Pharma Set for Upcoming Dividend Payment - Intellectia AI
Royalty Pharma (NASDAQ:RPRX) CFO Sells $4,924,629.36 in Stock - MarketBeat
Terrance Coyne Sells 108,424 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Terrance Coyne Sells 20,163 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy? - Finviz
AE Wealth Management LLC Lowers Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Royalty Pharma (RPRX) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Urist Marshall, royalty pharma EVP, sells $821,810 in shares By Investing.com - Investing.com South Africa
Urist Marshall, royalty pharma EVP, sells $821,810 in shares - Investing.com
Royalty Pharma (RPRX) Stock Analysis: Analysts See 15% Upside Potential - DirectorsTalk Interviews
Marshall Urist Sells 20,000 Shares of Royalty Pharma (NASDAQ:RPRX) Stock - MarketBeat
Mirae Asset Global Investments Co. Ltd. Buys 31,045 Shares of Royalty Pharma PLC $RPRX - MarketBeat
Strs Ohio Lowers Stock Holdings in Royalty Pharma PLC $RPRX - MarketBeat
Is Royalty Pharma (RPRX) Still Attractive After A 35% One Year Share Price Gain - Yahoo Finance
Royalty Pharma stock hits 52-week high at $41.71 By Investing.com - Investing.com India
Royalty Pharma (NASDAQ:RPRX) Hits New 1-Year HighShould You Buy? - MarketBeat
Royalty Pharma Plc Stock (RPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Royalty Pharma Plc Stock (RPRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Coyne Terrance P. | EVP & CFO |
Feb 02 '26 |
Sale |
42.08 |
108,424 |
4,562,905 |
30,167 |
| Coyne Terrance P. | EVP & CFO |
Feb 04 '26 |
Sale |
43.29 |
20,163 |
872,913 |
22,885 |
2.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):